Data Dictionary: National Cancer Registry (RON) (Portugal): Difference between revisions
From Beacon
No edit summary |
No edit summary |
||
| Line 83: | Line 83: | ||
| B symptoms | | B symptoms | ||
|- | |- | ||
| | | Tumour regression | ||
|- | |- | ||
| Estrogen receptors | | Estrogen receptors | ||
| Line 143: | Line 143: | ||
| Performance Status (ECOG) 0-4; 5 = unknown | | Performance Status (ECOG) 0-4; 5 = unknown | ||
|- | |- | ||
| Anti- | | Anti-tumour activity treatment | ||
|- | |- | ||
| Surveillance Yes/No | | Surveillance Yes/No | ||
| Line 161: | Line 161: | ||
| Vital status Alive/Dead | | Vital status Alive/Dead | ||
|- | |- | ||
| Cause of death | | Cause of death Tumour/Other cause/Unknown | ||
|- | |- | ||
| Date of last contact | | Date of last contact | ||
|} | |} | ||
Revision as of 00:40, 27 August 2024
Go back to Database: National Cancer Registry (RON) (Portugal) page
Source: Click here to learn more.
| Variables |
|---|
| Sex |
| Date of birth |
| Place of residence (at the time of diagnosis) |
| District or county |
| Date of symptom onset |
| Date of first observation |
| Date of first consultation |
| Date of therapeutic decision consultation (CDT) |
| Date of morphological pathology |
| ICDO-3 Topography |
| ICDO-3 Morphology |
| Laterality |
| Stage at presentation |
| If metastatic: location of metastases |
| Degree of differentiation (6th digit of the ICDO-3 code); 1=Grade I, well differentiated; Grade II, moderately differentiated; 3=Grade III, poorly differentiated; 4=Grade IV, undifferentiated; 8=not determined; 9=unknown |
| Clinical TNM cTX; cT0-cT4; cNx; cN0-cN3 M0; M1 |
| Clinical diameter (mm) |
| Pathological TNM pTX; pT0-pT4 pNx; pN0-pN3 M0; M1 |
| Pathological diameter (mm) |
| Stage (I-IV) |
| Positive/resected lymph nodes (number) |
| Ann Arbor I-IV; Unknown |
| RAI |
| Binet |
| FAB |
| ISS |
| Durie and Salmon |
| Hasenclever |
| IPI |
| FLIPI |
| CSS |
| Dukes |
| Gleason |
| Breslow |
| Ki67 |
| Ulceration |
| Focality |
| B symptoms |
| Tumour regression |
| Estrogen receptors |
| Progesterone receptors |
| HER2 |
| 4200-072 Porto |
| Sentinel lymph node Yes/No/Unknown |
| Genetic alterations |
| BRAF mutation |
| KRAS mutation |
| EGFR mutation |
| ALK rearrangement |
| RB1 mutation |
| P53 mutation |
| IDH1 mutation |
| ATRX mutation |
| MGMT methylation |
| Co-del(1p19q) |
| Del(11q) |
| Del(13q) |
| Del(17p) |
| t(11;14) |
| t(14;16) |
| t(4;14) |
| Trisomy 5 |
| Trisomy 9 |
| Trisomy 12 |
| Trisomy 15 |
| Somatic hypermutation of immunoglobulin heavy chains Present/Absent/Unknown/Not evaluated |
| Charlson comorbidity index |
| Performance Status (ECOG) 0-4; 5 = unknown |
| Anti-tumour activity treatment |
| Surveillance Yes/No |
| Treatment type Surgery Radiotherapy Cellular therapy Systemic treatment Other treatment |
| If systemic treatment: Access regimen (PAP, Conventional, Clinical trial) Regimen/Drug Start date End date Number of cycles administered |
| If surgery: Date Procedure Target intervention Surgical radicality |
| If radiotherapy: Start date End date Radiotherapy type Technique Irradiated site |
| If cellular therapy: Date Type |
| If other treatment: Date Type |
| Vital status Alive/Dead |
| Cause of death Tumour/Other cause/Unknown |
| Date of last contact |
